MAP2K7 and non-small cell lung carcinoma: Our study suggests that SRC and MEK co-inhibition by Saracatinib and PD0325901 can be a proof-of-concept treatment strategy since the combination acts mostly synergistically in inhibiting cell proliferation across a wide panel of NSCLC cell lines (Fig. 1).